Plasma Protein-Bound Cannabinoid Compositions for Controlled Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Smoking medical cannabis and opium poppy plant matter for medicinal purposes lacks control over dosing and is associated with detrimental effects, including carcinogens and pulmonary decline, due to varying concentrations of active ingredients and harmful smoke inhalation.
Innovation Solution
Development of water-soluble compositions where cannabinoids and opioids are bound to plasma proteins, allowing for quality-controlled, accurately dosed pharmaceutical compositions that mimic the pharmacological benefits of cannabis smoke without the harmful effects of inhalation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If medical cannabis is smoked for medicinal purposes, then pain relief and other therapeutic effects are achieved, but control over dosing is lost and harmful effects occur
Solution Approach 1:
The patent extracts and isolates specific cannabinoids from cannabis plant matter to create standardized pharmaceutical compositions. By separating the active ingredients from the whole plant material, the invention enables precise dosing control while maintaining therapeutic efficacy, directly resolving the contradiction between achieving pain relief and maintaining dosing control.
Solution Approach 2:
The invention changes the concentration parameters of active ingredients by creating formulations with standardized amounts of cannabinoids (e.g., 2.5mg, 5mg, 10mg, 20mg, 40mg, 80mg, 160mg). This parameter standardization allows patients to control dosing precisely while receiving reliable therapeutic effects, eliminating the variability inherent in smoking whole plant material.
2Reliability
If medical cannabis is smoked, then therapeutic benefits are obtained, but carcinogens are inhaled and pulmonary damage occurs
Solution Approach 1:
The patent extracts only the beneficial cannabinoid components from cannabis plant matter through processes like solvent extraction, supercritical fluid extraction, or carbon dioxide extraction. This separation removes harmful constituents including carcinogens and combustion byproducts while concentrating the therapeutic active ingredients, thereby eliminating pulmonary damage risks while preserving therapeutic benefits.
Solution Approach 2:
The invention uses intermediary substances such as lipids, lipoproteins, or other carriers to deliver cannabinoids to the body without requiring combustion. These intermediaries enable the active ingredients to be administered through non-smoking routes (e.g., inhalation of vaporized oil, oral administration, or injection), eliminating direct exposure to carcinogenic smoke while maintaining therapeutic efficacy.
3Quantity of substance
If cannabis plant matter is used, then active ingredients are available, but concentration varies and dosing precision is lost
Solution Approach 1:
The patent employs extraction methods (solvent extraction, supercritical fluid extraction, carbon dioxide extraction) to isolate cannabinoids from variable plant material. This extraction process concentrates the active ingredients and removes variability introduced by different plant sources, growing conditions, and plant parts, resulting in standardized compositions with precise, consistent dosing concentrations.
Solution Approach 2:
The invention standardizes the concentration parameter of active ingredients by creating formulations with defined amounts of cannabinoids. Through controlled extraction and formulation processes, the patent transforms variable plant material into products with predictable, precise concentrations (e.g., 2.5mg to 160mg per dose), enabling accurate dosing while maintaining adequate quantities of active ingredients for therapeutic effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The protein-bound cannabinoid and opioid compositions provide controlled, rapid absorption of active ingredients with enhanced bioavailability and targeted delivery, reducing the risks associated with smoking and varying concentrations, while maintaining pharmacological efficacy.
Implementation Method 1
cannabinoids and opioids are bound to plasma proteins
Data Source
AI summary
Embodiments of the invention relate to methods for the manufacture of a protein-bound cannabinoid, comprising: obtaining a cannabinoid or cannabis in a form selected from the group consisting of cannabis smoke, cannabis vapor, cannabinoid solution and cannabis extract, and combining the cannabis smoke, vapor, cannabinoid solution or cannabis extract with an aqueous solution or suspension comprising a plasma protein to form a protein-bound cannabinoid. Further embodiments relate to aqueous solutions comprising a plasma protein-bound cannabinoid and pharmaceutical compositions comprising cannabinoids bound to plasma protein.